Navigation Links
A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
Date:8/2/2008

SEATTLE, Aug. 2 /PRNewswire/ -- "The federal government's ability to more exactly measure the number of new HIV infections in the United States annually is a great statistical tool -- but that is all that it is. I interpret the new numbers this way: They remind us that HIV/AIDS continues to be a real public health problem in this country as well as in many developing nations around the globe. Despite recent setbacks in developing an effective vaccine to prevent HIV infection, I believe that a vaccine is our most promising weapon against new infections. The research community's commitment to find a vaccine must not waver."

Dr. Corey is the Principal Investigator of the HIV Vaccine Trials Network (HVTN) and co-director of the Vaccine and Infectious Diseases Institute, both at Fred Hutchinson Cancer Research Center in Seattle, WA.

About the HIV Vaccine Trials Network

The HVTN is an international collaboration of scientists and institutions whose goal is to accelerate the search for an HIV vaccine by sharing trial results and facilitating parallel, concurrent testing. The HVTN is a unique hybrid that combines the depth and diversity of the academic community and the flexibility of a commercial drug company. Working with industry and government, the HVTN seeks to expedite and coordinate the trial process, advancing vaccine candidates and building a body of knowledge about HIV vaccine trials. The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases, which is a component of the U.S. National Institutes of Health. The Network and NIAID have a close, cooperative working relationship, with shared attention to the intellectual and scientific issues.

Contact: Sarah Alexander

206-910-3801

salex@hvtn.org


'/>"/>
SOURCE HIV Vaccine Trials Network
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):